度普利尤单抗相关淋巴样反应:特应性皮炎患者的临床与病理特征
该回顾性观察性病例系列纳入2017年10月至2022年7月荷兰乌得勒支大学医学中心接受度普利尤单抗治疗的成人特应性皮炎患者14例,因治疗期间疑似皮肤T细胞淋巴瘤而评估。结论认为度普利尤单抗可导致可逆的良性淋巴样反应,模仿皮肤T细胞淋巴瘤但有独特组织病理特征。
要点
- 度普利尤单抗治疗特应性皮炎期间可出现临床疑似皮肤T细胞淋巴瘤的淋巴样反应。
- 淋巴样反应中位临床恶化时间4.0个月(IQR 1.4-10.0),治疗后活检均完全消退。
- 淋巴样反应组织病理特征包括表皮上部小深染淋巴细胞散在分布、CD4:CD8比值失调、CD30过表达,无CD2/CD3/CD5丢失。
核心结论
- 度普利尤单抗治疗可引起可逆的良性淋巴样反应,模仿皮肤T细胞淋巴瘤,但具有独特的组织病理学特征。
研究设计与样本
- 回顾性观察性病例系列,纳入2017年10月至2022年7月荷兰乌得勒支大学医学中心接受度普利尤单抗治疗的成人(≥18岁)特应性皮炎患者14例。
主要发现
- 14例患者中54.5%为男性,中位(IQR)年龄56(36-66)岁,因治疗期间症状恶化疑似皮肤T细胞淋巴瘤。
- 淋巴样反应患者表现为蕈样肉芽肿样症状,但组织病理不同:表皮上部小深染淋巴细胞散在分布、CD4:CD8比值失调、CD30过表达,无CD2/CD3/CD5丢失。
- 中位临床恶化时间4.0个月(IQR 1.4-10.0)。
- 治疗后活检显示所有患者淋巴样反应完全消退。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates. OBJECTIVE: To provide insight in the clinical and histopathologic features of patients with AD clinically suspected for CTCL during dupilumab treatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational case series included adult (≥18 years) patients with AD treated with dupilumab between October 2017 and July 2022 at the University Medical Center Utrecht in the Netherlands. MAIN OUTCOMES AND MEASURES: Relevant patient, disease, and treatment characteristics were evaluated. Skin biopsies before, during, and after treatment were collected and reassessed. RESULTS: Fourteen patients (54.5% male) with a median (IQR) age of 56 (36-66) years suspected for CTCL with deterioration of symptoms during dupilumab treatment were included. Of 14 patients, 3 were retrospectively diagnosed with preexistent mycosis fungoides (MF). Eleven patients with AD were eventually diagnosed with a lymphoid reaction (LR). These patients showed MF-like symptoms; however, histopathologic findings were different, and included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and CD30 overexpression, without loss of CD2/CD3/CD5. The median time to clinical worsening was 4.0 months (IQR, 1.4-10.0). Posttreatment biopsies showed complete clearance of the LR in all patients. CONCLUSIONS AND RELEVANCE: This study found that dupilumab treatment can cause a reversible and benign LR, which mimics a CTCL, though has distinctive histopathologic features.
引用
- Boesjes CM, van der Gang LF, Bakker DS, et al. Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatol. 2023. PMID: 37851456. doi:10.1001/jamadermatol.2023.3849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。